Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

InxMed Raises $50 Million for Resistance-Fighting Cancer Therapies

publication date: Mar 4, 2022

Nanjing InxMed raised $50 million in a Series B round to develop innovative therapies that target the stroma microenvironment and drug resistance for hard-to-treat solid tumors. The company's lead drug, IN10018,  is a selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor that is being tested in trials for  metastatic melanoma, platinum-resistant ovarian cancer and triple negative breast cancer. InxMed will use the funds to support clinical trials of IN10018 for multiple cancer types in the US and China, including starting pivotal trials. The Series B was led by CS Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here